soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction PDF) Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized Oral Semaglutide and Cardiovascular Outcomes
Pay in 4 interest-free payments of $7.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10





:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)


















